Comparing two chemotherapy combinations before stem cell transplant for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares two different chemotherapy drug combinations used before a stem cell transplant for multiple myeloma. The aim is to see if this new combination helps control the disease better before the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with multiple myeloma.
- Your cancer has not completely disappeared before the transplant.
- You are scheduled to have an autologous stem cell transplant within the next 12 months.
- Your major organs (like liver and heart) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a specific type of radiation (helical tomotherapy) in people with multiple myeloma who are planning an autologous stem cell transplant. It may help the study team understand how safe and effective this approach is when used during transplant preparation.
This trial tests whether the chemotherapy medicine treosulfan (Trecondi® Ideogen) works well and is safe for people with myeloma who are moving on to high-dose chemotherapy plus their own stem cell transplant. It may help strengthen the transplant “conditioning” treatment before the transplant.
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This Phase 2 trial tests whether a combination of anti-myeloma medicines given before stem cell transplant works well and is safe for people with multiple myeloma who also have kidney problems. It may help control the myeloma and prepare you for the transplant.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.